Brokerages Set Insmed, Inc. (NASDAQ:INSM) PT at $209.35

Posted by on Aug 13th, 2026

Shares of Insmed, Inc. (NASDAQ:INSM – Get Free Report) have been assigned an average rating of “Buy” from the twenty-six ratings firms that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, twenty-three have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $205.5217.

A number of equities research analysts have commented on the company. Mizuho set a $192.00 target price on Insmed in a research report on Tuesday, June 16th. Jefferies Financial Group reissued a “buy” rating and set a $175.00 price objective on shares of Insmed in a research report on Thursday, August 6th. HC Wainwright restated a “buy” rating on shares of Insmed in a report on Monday. Truist Financial restated a “buy” rating and issued a $195.00 price objective (up from $185.00) on shares of Insmed in a report on Monday. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $218.00 target price on shares of Insmed in a research report on Friday, August 7th.

View Our Latest Stock Report on INSM

Insider Activity at Insmed

In other news, insider Michael Alexander Smith sold 1,806 shares of the business’s stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $95.82, for a total value of $173,050.92. Following the sale, the insider directly owned 37,648 shares of the company’s stock, valued at approximately $3,607,431.36. The trade was a 4.58% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Roger Adsett sold 239,850 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $133.27, for a total transaction of $31,964,809.50. Following the completion of the transaction, the chief operating officer owned 98,744 shares in the company, valued at approximately $13,159,612.88. This represents a 70.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 294,440 shares of company stock valued at $37,758,548 over the last 90 days. Insiders own 2.10% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in INSM. Bank of New York Mellon Corp purchased a new position in shares of Insmed during the second quarter worth $139,966,000. S&CO Inc. acquired a new stake in shares of Insmed in the second quarter valued at $1,386,000. E. Ohman J or Asset Management AB raised its holdings in shares of Insmed by 48.7% in the 2nd quarter. E. Ohman J or Asset Management AB now owns 7,789 shares of the biopharmaceutical company’s stock valued at $830,000 after buying an additional 2,550 shares during the period. Handelsbanken Fonder AB raised its holdings in shares of Insmed by 180.9% in the 2nd quarter. Handelsbanken Fonder AB now owns 189,581 shares of the biopharmaceutical company’s stock valued at $20,213,000 after buying an additional 122,100 shares during the period. Finally, Wealthcare Advisory Partners LLC purchased a new stake in shares of Insmed in the 2nd quarter valued at $498,000.

Insmed Stock Down 0.2%

INSM stock opened at $132.28 on Thursday. The firm has a market cap of $28.89 billion, a PE ratio of -32.18 and a beta of 0.81. The company has a debt-to-equity ratio of 0.74, a quick ratio of 3.40 and a current ratio of 3.72. The firm’s 50 day moving average price is $106.86 and its 200-day moving average price is $128.44. Insmed has a one year low of $90.39 and a one year high of $212.75.

Insmed (NASDAQ:INSM – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.61. The firm had revenue of $425.49 million for the quarter, compared to analysts’ expectations of $395.50 million. Insmed had a negative return on equity of 123.94% and a negative net margin of 76.94%.The firm’s quarterly revenue was up 296.1% on a year-over-year basis. During the same period in the prior year, the firm posted ($1.70) earnings per share. On average, equities research analysts anticipate that Insmed will post -1.85 EPS for the current year.

Insmed News Summary

Here are the key news stories impacting Insmed this week:

  • Positive Sentiment: HC Wainwright maintained a Buy rating and raised its EPS forecasts across 2026–2030. Its estimates improved to losses of $0.31 per share for Q3 2026 and $0.49 for Q4, while forecasts increased to $1.62 for FY2027, $3.38 for FY2028 and $10.92 for FY2030. The upgrades suggest stronger expectations for Insmed’s commercial growth and eventual profitability.
  • Positive Sentiment: Insmed partnered with a patient group on a bronchiectasis study, potentially strengthening patient engagement and the company’s clinical evidence base in a key disease area. Insmed partners patient group on bronchiectasis study
  • Neutral Sentiment: The reported short-interest data showed zero shares and a zero-day days-to-cover ratio, indicating no meaningful short-position signal; however, the figures appear unreliable because the reported change was listed as “NaN.”
  • Negative Sentiment: COO Roger Adsett sold 239,850 shares for approximately $32.0 million at an average price of $133.27, reducing his holdings by 70.84%. Although insider sales can reflect personal financial planning, the size of the transaction may raise concerns about insider conviction and add near-term selling pressure. Insider trading filing
  • Negative Sentiment: JPMorgan reportedly lowered its expectations for Insmed’s stock price, a potentially bearish development that contrasts with HC Wainwright’s more constructive earnings outlook. Details of the revised target were not provided. JPMorgan lowers expectations for Insmed stock price

Insmed Company Profile

(Get Free Report)

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.

Featured Stories

Analyst Recommendations for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.